Boston Scientific (BSX) has taken its new investor relations VP from Abiomed (ABMD), the company known for the world’s smallest heart pump and AbioCor. Susan Lisa has served as the senior director of investor relations and corporate development at Abiomed since 2012, according to her LinkedIn profile. She will begin her role as VP of […]
Fourteen veterans will endure a different kind of bootcamp this week: one that helps prepare them for jobs in the medtech industry. The AdvaMed Medical Technology Veterans Program Bootcamp kicked off yesterday and runs through Sept. 24 in Washington, D.C. The program helps selected veterans apply skills built on the battlefield to civilian job applications, […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The product Abiomed (ABMD) has deemed to be the “world’s smallest heart pump” will be included on the Veterans Affairs‘ Federal Supply Schedule. The Danvers, Mass.-based announced today it’s landed a federal contract to make its Impella platform available through an automated online database to about 169 VA’s facilities and 42 Department of Defense hospitals in […]
What do Johnson & Johnson, FedEx and Verizon Communications have in common? Aside from being Fortune 500 companies, they’re also led by former members of the U.S. military. According to a new Kauffman Foundation study just released, veterans aren’t starting businesses like they used to, but they are definitely leading them. It makes sense, really, […]
Shares of Abiomed Inc. (NSDQ:ABMD) slipped nearly five percent on Wall Street this morning, after the FDA posted a warning letter admonishing the heart pump maker for marketing a device for uses it’s not cleared for. The federal watchdog agency said a May 12 review of Danvers, Mass.-based Abiomed’s advertising, product labels and website “indicate […]
Abiomed Inc.’s stock is up 51 percent for the first quarter, destroying both the S&P 500 and Dow Jones IHI index averages. Abiomed Inc. (NSDQ:ABMD) absolutely crushed it during the first quarter, riding the momentum of its Impella heart pump to a 51.2 percent increase in its share price. The Danvers, Mass.-based company closed 2010 […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Over-ambitious doctors seem to have prompted Abiomed Inc. (NASDAQ:ABMD) to close down a clinical trial of its flagship cardiac assist device. The Danvers, Massachusetts-based company pulled the plug on the Protect II trial of its Impella 2.5 heart pump "based on a futility determination at the planned interim analysis regarding the primary end-point, which the company views as likely to be due to unanticipated confounding variables related to the use of rotational atherectomy."
Genzyme Corp. (NASDAQ:GENZ) CEO Henri Termeer has cut his stake in Danvers, Massachusetts-based Abiomed Inc. (NASDAQ:ABMD) by about 5.4 percent over the past year.
The CEOs of three medical device makers sat down for a round-table discussion of the challenges and opportunities facing the industry at the annual AdvaMed MedTech conference in Washington, D.C. William Hawkins of Medtronic Inc. (NYSE:MDT), Stephen MacMillan of Stryker Corp. (NYSE:SYK) and Michael Minogue of Abiomed Inc. (NASDAQ:ABMD) spoke about upcoming changes to the 510(k) protocol, the user fee program, transparency initiatives and the steps they're taking to deal with healthcare reform.
Abiomed Inc. (NSDQ:ABMD) started a new education program for hospitals. The Danvers, Massachusetts-based company is selecting healthcare institutions to be training centers for its Impella cardiac assist devices. Abiomed wants hospitals to adopt protocols that include the early administration of its heart pumps for patients with distressed hearts. Abiomed said use of its devices reduces […]
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Abiomed Inc. (NSDQ:ABMD) makes cardiac assist devices powerful enough to pump more than a gallon of blood through the heart each minute and small enough to be placed inside the heart via catheter. It’s a highly specialized, highly competitive market that’s difficult to break into. At an investors meeting in Boston last week, the company […]